ImageneBio (NASDAQ:IMA) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of ImageneBio (NASDAQ:IMA) to a strong-buy rating in a research report sent to investors on Friday morning,Zacks.com reports.

Several other equities research analysts have also recently weighed in on IMA. Zacks Research cut ImageneBio from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. Weiss Ratings assumed coverage on ImageneBio in a research note on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Leerink Partners assumed coverage on ImageneBio in a research note on Friday. They set an “outperform” rating and a $30.00 target price for the company. Wedbush decreased their target price on ImageneBio from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. Finally, Wall Street Zen upgraded ImageneBio to a “hold” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, ImageneBio has a consensus rating of “Moderate Buy” and a consensus price target of $33.67.

ImageneBio Trading Up 8.3%

Shares of NASDAQ:IMA opened at $8.00 on Friday. The business has a 50-day moving average price of $9.65 and a 200 day moving average price of $13.20. The company has a market capitalization of $32.04 million, a price-to-earnings ratio of -1.04 and a beta of 0.41. ImageneBio has a 12-month low of $7.24 and a 12-month high of $23.28.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.08. As a group, equities research analysts predict that ImageneBio will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BML Capital Management LLC grew its holdings in ImageneBio by 3.5% during the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock worth $4,750,000 after acquiring an additional 124,937 shares during the period. Aldebaran Capital LLC acquired a new position in ImageneBio during the first quarter worth $317,000. Goldman Sachs Group Inc. grew its holdings in ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after acquiring an additional 29,369 shares during the period. Finally, XTX Topco Ltd grew its holdings in ImageneBio by 350.6% during the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after acquiring an additional 43,924 shares during the period. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.